Skip to content
Company Analysis

Bionano Genomics, Inc. BNGO

A comprehensive view of key metrics, scores, and financial health for Bionano Genomics, Inc.

Overview of Bionano Genomics, Inc.

BNGO NCM
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Micro Cap
Bionano Genomics, Inc. (BNGO), is a Micro Cap company, in the Medical Instruments & Supplies industry, last closed at $1.16, about 86.2% overvalued vs fair value, -68.2% 1Y return, ranked 1012/1122 in sector.
USD 1.16
-2.52%
(Delayed)
• Vol 90d: 66.8%
52-Week Range
Market Cap
$12.87M
Enterprise Value
$26.46M
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Good
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 53%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://bionano.com
HQ San Diego, CA
Employees 98
Fiscal year Dec 31

Next Events

Earnings Aug 13 Estimated

Fair Value Snapshot

Bear Base Bull
$0
$0
$1
Current: $1.16 -86% vs base

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$28.5M
-7.4%%
Gross Profit
$13.2M
3369.7%%
Operating Income (GAAP)
$-33.3M
56.3%%
EBITDA
$-16.3M
82.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
46.3%
Fair

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Bionano Genomics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
30
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
15
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing BNGO's balance between Growth (52.3%), Profitability (16.0%), and Safety (31.7%). Growth 52% Safety 32% Profitability 16%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

49th percentile vs peers
50
Key Signals
EPS Growth YoY 85.3% 87p Revenue CAGR 3Y 19.6% 74p Rev Growth YoY -14.8% 15p Asset Growth YoY -64.2% 1p
Strengths
  • EPS Growth YoY in top 20% of peers (85.3%, 87th percentile)
Risks
  • Rev Growth YoY in bottom 20% of peers (-14.8%)

Profitability

15th percentile vs peers
15
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

30th percentile vs peers
30
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Bionano Genomics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$0.16
- - -
-86.2% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000